Gil, Jesús http://orcid.org/0000-0002-4303-6260
Article History
First Online: 26 October 2023
Competing interests
: J.G. has acted as a consultant for Unity Biotechnology, Geras Bio, Myricx Pharma Ltd and Merck KGaA. J.G. owns equity in Geras Bio and share options in Myricx Pharma Ltd, and is a named inventor in UK Medical Research Council (MRC) and Imperial College patents related to senolytic therapies. J.G.’s laboratory receives research funding from Pfizer at present. Unity Biotechnology funded research on senolytics in J.G.’s laboratory in the past.